Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Japan Weighs Legal Framework for Pharmaceutical Data Protection; JPMA Sees Opportunity for Reform
August 19, 2025
-
REGULATORY Japan Approves First SGLT2 Generics, 12 Firms Pile into Vimpat Ahead of December Listing
August 18, 2025
-
REGULATORY Novartis’ Radioligand Therapy, Other New Meds Up for Japan Panel Review on Aug. 22
August 12, 2025
-
REGULATORY Japan Nears Approval for 1st Biosimilars of Actemra, Simponi, and Ranmark
August 12, 2025
-
REGULATORY Japan Approves FY2026 Budget Guidelines, Natural Increase at 400 Billion Yen
August 12, 2025
-
BUSINESS Ashraf Al-Ouf Named President of Bayer Yakuhin and Bayer Holding in Japan
August 8, 2025
-
REGULATORY Public-Private Council WG to Focus on Innovation Evaluation for FY2026 Reform: Official
August 8, 2025
-
BUSINESS Sumitomo Eyes Conditional Nod for iPS Cell Therapy for Parkinson’s in FY2025
August 8, 2025
-
BUSINESS PeptiDream Probes Ex-COO over Unauthorized Provision of Reagents to Academia
August 8, 2025
-
REGULATORY Industry Urges “Objective Review First” for CEA Reform; Payers Push for Expansion
August 7, 2025
-
REGULATORY Welireg, Airwin, Talvey and More Set for NHI Listing; Premiums Wiped Out by “Zero” Rule
August 7, 2025
-
REGULATORY DPO Floats Premium Expansion, Relaxed Criteria towards FY2026 Reform
August 7, 2025
-
REGULATORY Chuikyo Rules Out Long-Term Care Costs in Leqembi CEA, Confirms Price Cut
August 7, 2025
-
REGULATORY Wegovy, Leqvio, Phozevel to Face CEA-Linked Price Cuts in November
August 7, 2025
-
REGULATORY MHLW Device Review Chief Pledges Evidence-Based Approvals amid Diversifying Technologies
August 6, 2025
-
REGULATORY MHLW Trial Office Head Vows to Make Japan a Preferred Site for Clinical Studies
August 5, 2025
-
REGULATORY Wage-Based Price Premiums on Drugs Not an Option, Says MHLW Insurance Chief
August 4, 2025
-
BUSINESS Nihon Chouzai to Go Private through Tender Offer Backed by Advantage Partners
August 1, 2025
-
ORGANIZATION Japan Society Poised to Set Out Criteria to Standardize Regional Formularies, Eyes August Release
July 31, 2025
-
REGULATORY MHLW to Link GS1 and YJ Codes in Public Database, Launch Planned for FY2028
July 30, 2025
ページ
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…